Header

UZH-Logo

Maintenance Infos

Transfusion-transmissible infections and transfusion-related immunomodulation


Buddeberg, F; Beck-Schimmer, B; Spahn, D R (2008). Transfusion-transmissible infections and transfusion-related immunomodulation. Best Practice & Research: Clinical Anaesthesiology, 22(3):503-517.

Abstract

The risk of acquiring a transfusion-transmitted infection has declined in recent years. However, after human immunodeficiency virus and hepatitis B and C virus transmission were successfully reduced, new pathogens are threatening the safety of the blood supply, especially in the face of rising numbers of immunocompromised transfusion recipients. Despite new standards in the manufacture and storage of blood products, bacterial contamination still remains a considerable cause of transfusion-related morbidity and mortality. Better allograft survival in kidney transplant patients and higher cancer recurrence rate in surgical oncology patients after allogeneic blood transfusions highlighted a previously underestimated side-effect: transfusion-related immunomodulation (TRIM). The precise pathomechanism still remains uncertain; however, its mostly deleterious effects--such as a higher incidence of postoperative or nosocomial infections--is increasingly accepted. Although transfusion-related immunomodulation is thought to be mediated mainly by donor white blood cells, the benefit of leukoreduction on overall mortality and on infectious complications is highly debatable.

Abstract

The risk of acquiring a transfusion-transmitted infection has declined in recent years. However, after human immunodeficiency virus and hepatitis B and C virus transmission were successfully reduced, new pathogens are threatening the safety of the blood supply, especially in the face of rising numbers of immunocompromised transfusion recipients. Despite new standards in the manufacture and storage of blood products, bacterial contamination still remains a considerable cause of transfusion-related morbidity and mortality. Better allograft survival in kidney transplant patients and higher cancer recurrence rate in surgical oncology patients after allogeneic blood transfusions highlighted a previously underestimated side-effect: transfusion-related immunomodulation (TRIM). The precise pathomechanism still remains uncertain; however, its mostly deleterious effects--such as a higher incidence of postoperative or nosocomial infections--is increasingly accepted. Although transfusion-related immunomodulation is thought to be mediated mainly by donor white blood cells, the benefit of leukoreduction on overall mortality and on infectious complications is highly debatable.

Statistics

Citations

Altmetrics

Downloads

130 downloads since deposited on 27 Oct 2008
17 downloads since 12 months
Detailed statistics

Additional indexing

Item Type:Journal Article, refereed, further contribution
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Institute of Anesthesiology
Dewey Decimal Classification:610 Medicine & health
Language:English
Date:2008
Deposited On:27 Oct 2008 08:27
Last Modified:21 Nov 2017 13:34
Publisher:Elsevier
ISSN:1753-3740
Publisher DOI:https://doi.org/10.1016/j.bpa.2008.05.003
PubMed ID:18831300

Download

Download PDF  'Transfusion-transmissible infections and transfusion-related immunomodulation'.
Preview
Content: Accepted Version
Filetype: PDF
Size: 1MB
View at publisher